8 / 43
OS IN mRCC
Risk factors for survival included anaemia, thrombocytosis, neutrophilia,
hypercalcaemia, KPS <80%, and <1 year from diagnosis to treatment.
Time since start of treatment, months
12
24
36
48
60
0
40
20
0
100
80
60
OS, %
p<0.0001
Median survival
30 months
14 months
5 months
Time from start of IFN-α, years
0
2
16
14
4
10
8
6
Proportion surviving
0.0
0.2
0.4
0.6
0.8
1.0
0 risk factor (n=83)
1 or 2 risk factors (n=287)
3, 4 or 5 risk factors (n=93)
Risk factors KPS <80%, time from diagnosis to IFN-α <1 year, low
serum haemoglobin, high corrected calcium (>2.5mmol/L [10mg/dL]),
high LDH (>1.5
×
ULN).
12
Before VEGF-targeted therapies (IFN-ɑ)
1
VEGF-targeted therapies
2
Median survival
43 months
23 months
8 months
No. factors
0
1–2
3–6
Risk group
Favourable
Intermediate
Poor
Motzer RJ, et al. J Clin Oncol 2002;20:289–96
Heng DY, et al. Lancet Oncol 2013;14:141−48